Osteopontin is proinflammatory in experimental autoimmune uveitis

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 10, 2006, Pages 4435-4443

  Hikita, Sherry T ^a   Vistica, Barbara P ^b   Jones, Heather R ^a   Keswani, Jennifer R ^a   Watson, Morgan M ^a   Ericson, Vivian R ^a   Ayoub, George S ^a   Gery, Igal ^b   Clegg, Dennis O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; OSTEOPONTIN; AUTOANTIBODY; EYE PROTEIN; RETINOL BINDING PROTEIN; RETINOL-BINDING GLYCOPROTEIN; SIALOGLYCOPROTEIN; SPP1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE UVEITIS; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; GRANULOMA; IMMUNOFLUORESCENCE; LEUKOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MICROGLIA; MORBIDITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINITIS; UVEITIS; ANIMAL; AUTOIMMUNE DISEASE; BLOOD; C57BL MOUSE; CONFOCAL MICROSCOPY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; INJECTION; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; VITREOUS BODY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INJECTIONS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MICROSCOPY, CONFOCAL; OSTEOPONTIN; RETINOL-BINDING PROTEINS; SIALOGLYCOPROTEINS; T-LYMPHOCYTES; UVEITIS, POSTERIOR; VITREOUS BODY;

EID: 33750587420     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0064     Document Type: Article

References (62)

1. Magone MT, Whitcup SM. Mechanisms of intraocular inflammation. Chem Immunol. 1999;73:90-119.
2. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1-13.
3. Nusenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. 3rd ed. Philadelphia, PA: Mosby; 2004.
4. Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats: immunopathogenic mechanisms and histologic features. Invest Ophthalmol Vis Sci. 1985;26:1-9.
5. Caspi RR, Roberge FG, Chan CC, et al. A new model of autoimmune disease: experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 1988;140:1490-1495.
6. Caspi RR, Chan CC, Wiggert B, Chader GJ. The mouse as a model of experimental autoimmune uveoretinitis (EAU). Curr Eye Res. 1990;9(suppl):169-174.
7. Chan CC, Caspi RR, Ni M, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun. 1990;3:247-255.
8. Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 1999;40:3177-3185.
9. Forrester JV, Dick AD, McMenamin PG. The Eye. 2nd ed. Philadelphia: WB Saunders; 2002.
10. Salinas-Carmona MC, Nussenblatt RB, Gery I. Experimental autoimmune uveitis in the athymic nude rat. Eur J Immunol. 1982;12:480-484.
11. Caspi RR, Roberge FG, McAllister CG, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986;136:928-933.
12. Caspi RR. Immune mechanisms in uveitis. Springer Semin Immunopathol. 1999;21:113-124.
13. Forrester JV, Huitinga I, Lumsden L, Dijkstra CD. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res. 1998;17:426-437.
14. Gullapalli VK, Zhang J, Pararajasegaram G, Rao NA. Hematopoietically derived retinal perivascular microglia initiate uveoretinitis in experimental autoimmune uveitis. Graefes Arch Clin Exp Ophthalmol 2000;238:319-325.
15. Rao NA, Kimoto T, Zamir E, et al. Pathogenic role of retinal microglia in experimental uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:22-31.
16. Foxman EF, Zhang M, Hurst SD, et al. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 2002;168:2483-2492.
17. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16:885-893.
18. Weber GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev. 1996;7:241-248.
19. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860-864.
20. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14:608-616.
21. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000;81:373-390.
22. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723-749.
23. Adler B, Ashkar S, Cantor H, Weber GF. Costimulation by extracellular matrix proteins determines the response to TCR ligation. Cell Immunol. 2001;210:30-40.
24. Weber GF, Zawaideh S, Hikita S, et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol. 2002;72:752-761.
25. O'Regan AW, Chupp GL, Lowry JA, et al. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol. 1999;162:1024-1031.
26. Guo H, Cai CQ, Schroeder RA, Kuo PC. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol. 2001;166:1079-1086.
27. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem. 2000;275:16666-16672.
28. O'Regan AW, Hayden JM, Body S, et al. Abnormal pulmonary granuloma formation in osteopontin-deficient mice. Am J Respir Crit Care Med. 2001;164:2243-2247.
29. Liaw L, Birk DE, Ballas CB, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998;101:1468-1478.
30. Weber GF, Ashkar S. Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. Brain Res Bull. 2000;53:421-424.
31. Singh K, Sirokman G, Communal C, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999;33:663-670.
32. Mark MP, Prince CW, Gay S, Austin RL, Butler WT. 44-kDal bone phosphoprotein (osteopontin) antigenicity at ectopic sites in newborn rats: kidney and nervous tissues. Cell Tissue Res. 1988;251:23-30.
33. Thayer JM, Giachelli CM, Mirkes PE, Schwartz SM. Expression of osteopontin in the head process late in gastrulation in the rat. J Exp Zool. 1995;272:240-244.
34. Shin SL, Cha JH, Chun MH, Chung JW, Lee MY. Expression of osteopontin mRNA in the adult rat brain. Neurosci Lett. 1999;273:73-76.
35. Ichikawa H, Yamashita K, Takano-Yamamoto T, Sugimoto T. Osteopontin-immunoreactivity in the rat trigeminal ganglion and trigeminal sensory nuclei. Brain Res. 2001;919:147-154.
36. Ju WK, Kim KY, Cha JH, et al. Ganglion cells of the rat retina show osteopontin-like immunoreactivity. Brain Res. 2000;852:217-220.
37. Hikita ST, Cann GM, Wingerd KL, et al. Integrin alpha4beta1 (VLA-4) expression and activity in retinal and peripheral neurons. Mol Cell Neurosci. 2003;23:427-439.
38. Hashimoto M, Koda M, Ino H, et al. Upregulation of osteopontin expression in rat spinal cord microglia after traumatic injury. J Neurotrauma. 2003;20:287-296.
39. Kim SY, Choi YS, Choi JS, et al. Osteopontin in kainic acid-induced microglial reactions in the rat brain. Mol Cells. 2002;13:429-435.
40. Lee MY, Shin SL, Choi YS, et al. Transient upregulation of osteopontin mRNA in hippocampus and striatum following global forebrain ischemia in rats. Neurosci Lett. 1999;271:81-84.
41. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
42. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin- deficient mice. J Immunol. 2002;168:2096-2099.
43. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol. 2003;3:483-492.
44. Kim MD, Cho HJ, Shin T. Expression of osteopontin and its ligand, CD44, in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004;151:78-84.
45. Zhang M, Chan CC, Vistica B, et al. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol. 2000;103:189-194.
46. Redmond TM, Sanui H, Hu LH, et al. Immune responses to peptides derived from the retinal protein IRBP: immunopathogenic determinants are not necessarily immunodominant. Clin Immunol Immunopathol 1989;53:212-224.
47. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998;152:353-358.
48. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med. 1990;171:1931-1942.
49. Agnihotri R, Crawford HC, Haro H, et al. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001;276:28261-28267.
50. Gao YA, Agnihotri R, Vary CP, Liaw L. Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. Matrix Biol. 2004;23:457-466.
51. Ohta K, Wiggert B, Taylor AW, Streilein JW. Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci. 1999;40:2010-2018.
52. Xu H, Forrester JV, Liversidge J, Crane IJ. Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest Ophthalmol Vis Sci. 2003;44:226-234.
53. Zohar R, Suzuki N, Suzuki K, et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol. 2000;184:118-130.
54. Zhu B, Suzuki K, Goldberg HA, et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol. 2004;198:155-167.
55. Koistinaho J, Yrjanheikki, J. Inflammation and potential anti-inflammatory approaches in stroke. Neuroinflammation: Mechanisms and Management. 2nd ed. Totowa, NJ; Humana Press; 2003:189-213.
56. Chen L, Yang P, Kijlstra A. Distribution, markers, and functions of retinal microglia. Ocul Immunol Inflamm. 2002;10:27-39.
57. Penfold PL, Provis JM, Liew SC. Human retinal microglia express phenotypic characteristics in common with dendritic antigen-presenting cells. J Neuroimmunol. 1993;45:183-191.
58. Matsubara T, Pararajasegaram G, Wu GS, Rao NA. Retinal microglia differentially express phenotypic markers of antigen-presenting cells in vitro. Invest Ophthalmol Vis Sci. 1999;40:3186-3193.
59. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol. 1994;145:1450-1462.
60. Lampe MA, Patarca R, Iregui MV, Cantor H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol. 1991;147:2902-2906.
61. Benihoud K, Salone B, Esselin S, et al. The role of IL-6 in the inflammatory and humoral response to adenoviral vectors. J Gene Med. 2000;2:194-203.
62. Wallace GR, Whiston RA, Stanford MR, et al. The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU). Clin Exp Immunol. 1999;118:364-370.